

CURRICULUM VITAE OF PAUL G. KING, PHD

33 Hoffman Avenue, Lake Hiawatha, NJ 07034-1922
Send E-mail to paulgkingphd@gmail.com; or drking@gti.net
Telephone: (973) 997-1321

An experienced professional having broad analytical, facilities and systems, current good manufacturing practice (CGMP), and management experience with a record of high-level responsibility and proven accomplishment in pharmaceuticals chemicals, and biocides. Analytical perspective and results oriented. Key strengths:

Leader and manager of people, change, organizational units and projects from inception to completion and beyond to meet customer, quality, regulatory and business expectations.

Innovative scientist who finds or invents and develops cost-effective methodologies and procedures.

Problem solver/innovator with the ability to comprehend, and to successfully interpret, the complex interrelationships among customers, quality, regulations, processes, operations, and technologies.

Analytical chemist with excellent written and verbal skills as well as in-depth understanding of chemistry, pharmaceuticals and all facets of the pharmaceutical industry [CGMP; GLP; GAMP; ISO 9000; TQM; PAT; Commissioning; Qualification; Validation; mission, vision and values statements; general policies; standard operating procedures (“SOPs”); design, development and validation of test methods, equipment, processes, and supplies; scheduling; staffing and training; materials definition; methods; and systems management].

PROFESSIONAL EXPERIENCE:

Genetic Consultants of New Jersey, Parsippany, NJ 2009 – Date
DIRECTOR

Oversee the day-to-day operation of this satellite office of ASD Centers LLC.

FAME Systems, Lake Hiawatha, NJ 2001 – Date
CONSULTANT

Working with clients, including the United States Food and Drug Administration (FDA) and public advocacy groups, to:

- Provide training in, insight into, and analysis of the requirements of the drug CGMP statutes and regulations as well as their impacts and cost effective approaches to pro-active quality-based systems for compliance with said requirements. [**Note:** Areas addressed include method/process development, validation, and manufacturing, and electronic records.]
- Address public health and safety issues associated with current industry practices, FDA guidances and initiatives, and the CDC’s handling of the “mercury in medicines” issues.

In addition, currently oversee two Internet websites:

- <http://www.dr-king.com> on which my general background and other information is maintained.

- <http://www.mercury-freedrugs.org> on which pertinent advocacy-related articles are posted

Pro bono Science Advisor to CoMeD, NCOW, and other not-for-profit organizations who seek my advice.

R & D Scientific Corporation, Flanders, NJ 2000 – 2001
VP of QUALITY MANAGEMENT

Spearheaded the conversion of manufacturing systems from *ad hoc* into documented systems that complied with the strictures of ISO 9001:1994.

Generated requisite policy, SOP, work instruction and tool documents for the quality management and related functions and provided quality systems guidance to the others.

Rewrote the Users Manual for their main product so that it actually matched that system's functionalities.

Paul G. King Consulting, Lake Hiawatha, NJ 1995 – 2000
CONSULTANT

Worked with a variety of clients to solve their problems, develop and validate test methods and procedures, design robust processes, and improve their quality.

Audited proposals, systems, and suppliers as well as generated documents, methods, designs and systems as needed.

Nutro Laboratories, Inc., South Plainfield, NJ 1995 – 1996
DIRECTOR OF QUALITY

To improve product quality, started the critical checking of data and effected production changes that upgraded product quality to meet Company and customer expectations.

Furnished the President of Nutro with detailed information on quality problems, their root causes and changes that could either eliminate the problem or reduce the risk of a recurrence.

Sidmak Laboratories, Inc., East Hanover, NJ 1992 – 1994
DIRECTOR OF QUALITY CONTROL

In order to meet the expectations of the FDA, took charge of the development and validation of methods; reorganized operations; restructured lab audit and control procedures; and upgraded training and staff. [**Note:** The FDA's concerns were addressed.]

To address overcrowding and productivity, designed, equipped, and staffed two new laboratories within a \$3MM budget to meet ISO/IEC Guide 25 (now, ISO 17025) competency standards.

Implemented systems for: acquisition, evaluation and archival of all data; qualification of instruments and analysts; demonstration of analyst/equipment "suitability;" and critical evaluation of results.

Overall, lab productivity more than doubled.

Biocraft Laboratories, Inc., Fair Lawn, NJ 1986 – 1992
DIRECTOR LABORATORY QUALITY ASSURANCE - 5.5+ years

Oversaw the auditing of the Laboratory and implemented a validated LIMS system.

Developed and validated stability-indicating methods for various bulk pharmaceuticals using HPLC and cleaning methods using UV spectroscopy.

To speed the registration of Cephalexin, developed and validated a sub-ppm HPLC method for detecting possible penicillin contamination that the FDA accepted by.

So that the drug product tested in a clinical trial could be produced reliably, developed a process, and the analytical controls, for the manufacture of the drug Sucralfate in China.

Biocraft Laboratories, Inc., Fair Lawn, NJ 1986 – 1992

MANAGER OF QUALITY CONTROL LABORATORY - 0.5 year

Developed improved HPLC, GC, and titrimetric methods for ingredient testing.
Managed a Bulk Pharmaceutical Chemical Quality Laboratory that passed FDA Inspection and met the NJ DEP competency standards for the environmental testing it performed.

At-Sea Incineration, Parsippany, NJ 1985 – 1986

MANAGER OF LABORATORY OPERATIONS –

Oversaw all aspects of both the company's laboratory operations and the activities of the contract laboratories that performed testing for the company.

Berlex Laboratories, Cedar Knolls, NJ 1983 – 1984

SENIOR SCIENTIST –

Led the reorganization of the laboratory that increase its productivity and raised its stature.

Developed and improved analytical methods in support of Schering AG's drug discovery efforts.

Developed improved operational protocols and test procedures that improved laboratory productivity and the quality of the result values reported.

Found novel HPLC separation approaches for chiral compounds and chiral mixtures that improved component separation and quantitation.

BASF Wyandotte, Fairfield, NJ 1981 – 1983

SENIOR RESEARCH SCIENTIST –

Spearheaded International BASF Corporate Team that selected the Laboratory Information Management System (LIMS) vendor to be used by BASF worldwide.

Worked with German and Japanese scientists to evaluate and establish the ruggedness and utility of a key analytical method that I had developed.

Led Analytical Method Team that developed innovative methods for residue, impurity and actives for several biocides.

Designed and oversaw the installation of a state-of the-art gas distribution system for the laboratories.

Developed method for manufacturing "acetamide" HPLC columns that was critical for the analysis of the active and impurities in the herbicide POAST.

American Cyanamid, West Windsor, NJ 1976 – 1981

RESEARCH SCIENTIST –

Developed analytical methods and techniques for a variety of research and approved biocides.

Discovered and developed an impurity method for the analysis of N-nitroso-amine impurities in chemical compounds that allowed the approximate ppm or ppb level to be measured even where the structures of the impurities were not known.

Led team that redeveloped the process and analytical controls for a nitrated herbicide. [**Note:** This process improved process safety, throughput and costs.]

Supervised the successful overhaul of Puerto Rican laboratory operations for LEVAMISOL after the FDA had the facility “red tagged” – in less than two (2) months lab operation was brought into compliance.

Developed modernized Phase Solubility purity methodology for AVENGE.

Led corporate committee on HPLC, and oversaw the critical evaluation of laboratory equipment.

United States Army, Walter Reed General Hospital, Washington, DC 1969 – 1971
PHYSICAL SCIENCE ASSISTANT – MOS: 01F20

Worked as clinical chemist and phlebotomist at the hospital.

Improved the sample handling and the precision and reliability of several continuous-flow, air-segmented automated analysis systems.

Won the Serviceman of the Quarter awards for the hospital, Walter Reed General Hospital, and the post, Walter Reed Army Medical Center.

Rose in rank from E-1 to the first in my unit to be promoted to E-5 (Specialist 5) in less than 18 months.

EDUCATION:

Postdoctoral Fellow at THE UNIVERSITY OF GEORGIA, Athens, GA where I worked for Dr. L. B. “Buck” Rogers and helped develop an SCF system, an Enzyme Analysis System and improved the operation of a Laboratory Data Acquisition System.

Ph.D., ANALYTICAL CHEMISTRY, EMORY UNIVERSITY, Atlanta, GA. [In 1974, my dissertation, “The Automated Development of Analytical Methods,” won Sigma Xi award for excellence.]

M. S., INORGANIC CHEMISTRY, EMORY UNIVERSITY, Atlanta, GA. [My 1969 thesis dealt with the synthesis of Tantalum (V) chloro-alkoxide coordination compounds containing β -di-ketone ligands.]

B.A., CHEMISTRY (ACS Certified), VANDERBILT UNIVERSITY, Nashville, TN, 1967.

TECHNICAL TRAINING

TECHNICAL DEGREE in “Computer Programming and Systems Analysis.” [A 1971 honor graduate from COMPUTER LEARNING CENTERS, INC., Rockville, MD.]

Technical Courses on:

- ❖ Quality Management (2001),
- ❖ Aseptic Processing (2001), 21 CFR 11 (1999);
- ❖ How To Prepare For Your FDA Inspection: A Practical Approach (1999);
- ❖ FDA Global Inspections (1998);
- ❖ Current FDA Views on Pharmaceutical Laboratory Operations and CGMPs (1998);

- ❖ Computer Validation and the FDA (1997);
- ❖ Interfacing with the FDA (1997);
- ❖ Pre-Approval Inspection (1996);
- ❖ Validation and Auditing (1995);
- ❖ Software Auditing (1993); Various Aspects of the Pharmaceutical Industry (1991);
- ❖ QA for Labs (1989);
- ❖ Perkin-Elmer LIMS/CLAS System; Lab Automation and QC (1984);
- ❖ Personnel Supervision (1981); and
- ❖ Management (1978).

CURRENT PROFESSIONAL AFFILIATIONS:

- ❖ American Chemical Society [ACS]
- ❖ International Society for Pharmaceutical Engineering [ISPE]
- ❖ Parenteral Drug Association [PDA] [resigned at the end of 2010]

DR. KING'S UNIVERSITY EDUCATION

- ❖ FROM September of 1974 until the end of 1975, Dr. King worked at THE UNIVERSITY OF GEORGIA in Athens, Georgia as a Graham Perdue Postdoctoral Fellow and Assistant Professor to Dr. L. B. (Buck) Rogers, Graham Perdue Professor. There he was, among other things, the System Manager, Systems Analyst, and Programmer for a Multi-User Hewlett Packard Minicomputer. Research efforts included the design and the construction of a computer-controlled system for constant-temperature (± 0.01 °C) comparative study of enzymatic reaction rates of immobilized enzymes to the rates using the soluble enzyme.
- ❖ From mid-May of 1971 through: August of 1973, Dr. King attended EMORY UNIVERSITY in Atlanta, Georgia in a Ph.D. program under Dr. Stan Deming (who is currently at The University of Houston) that awarded him a Ph.D. in December of 1974 that was officially conferred upon him in June of 1975. Dr. King's major field of endeavor was Analytical Chemistry with minors in Inorganic Chemistry and Physical Chemistry. In Dr. King's Ph.D. program, he:
 - A. Partially designed and then constructed, installed, debugged, and validated a full bi-directional parallel multiplexed external interface to a **PDP-9** Minicomputer.
 - B. Designed, constructed, installed, debugged, and validated a remote interface to **PDP-9** for the robot, **MADAM** (**M**achine for the **A**utomated **D**evelopment of **A**nytical **M**ethods).
 - C. Designed and constructed the power systems, controls and critical components for **MADAM**.
 - D. Debugged the operation of **MADAM** and validated that **MADAM** met or exceeded its hardware design specifications.
 - E. Working from a version of **FOCAL**[™] (a DEC interactive, interpretative language similar to BASIC) written for a **PDP-15 (FOCAL.LAL)**, Dr. King researched this computer's machine language; dissected the core coding needed for this project; and generated his own version of **FOCAL (FOCAL.PGK, version 1)**.
 - F. Wrote, debugged, and validated key machine-code patches to **FOCAL.PGK (Version 1A)** for the required data acquisition and control subroutines that provided real-time control and data acquisition capabilities for **MADAM**.
 - G. Generated, programmed, debugged, and verified the performance of his own "**SIMPLEX**" direct-search algorithms that were used by the robot to adaptively search for an "Optimum" as defined by Dr. King.
 - H. Selected a simple colorimetric analysis method for the determination of formaldehyde for his initial study; prepared the reagents needed by the robot, primed the eight (8) reagent delivery pumps and checked that the robot's component systems for acquisition (1) and system control (8) were operating as designed.
 - I. Generated a simple "optimum" (Absorptivity of the colored reaction product); started the robot's search for the optimum "greatest Absorptivity" using

“**EXPLEX**,” his modified **SIMPLEX** search algorithm; and monitored the performance of **MADAM** as the robot first found the region of optimum Absorptivity and then tracked it.

- J. Following mapping, he reviewed and verified all of the data and generated the appropriate reports.
- K. Then, selected a more complicated colorimetric test having more variables and repeated steps **G** through **J**.
- L. Finally, wrote his dissertation summarizing his research and findings, submitted the final document for review by the department, and defended his dissertation and findings in an open discussion that included faculty from all divisions of the Chemistry Department. [**Note:** In recognition of Dr. King’s contribution to science in chemistry, automation, and process control, his copyrighted dissertation, “*Automated Development of Analytical Methods*,” (ADAM) received a **SIGMA XI**’s annual award for scientific excellence.

- ❖ From September of 1971 through: April of 1969, Dr. King attended EMORY UNIVERSITY in Atlanta, Georgia in a Ph.D. program under Dr. Ronald C. Johnson that admitted him to Ph.D. candidacy and, in March 1969, awarded him an M.S. in Inorganic Chemistry. In Dr. King’s original Ph.D. program, he:
 - A. Studied Inorganic, Physical, Physical and Organic Chemistry.
 - B. Prepared, characterized and studied several novel Tantalum (V) chloro-alkoxide complexes with β -di-ketone ligands.
 - C. Worked as a laboratory teaching assistant and tutor.
 - D. Wrote his thesis on “The Coordination Chemistry of Tantalum (V).”

In addition, Dr. King holds an ACS Certified B.A. in Chemistry with a minor in Physics from Vanderbilt University, Nashville, Tennessee (awarded in 1967).

DR. KING'S ON-GOING TECHNICAL TRAINING

- A. Dr. King was certified as an **ASQ-Trained Quality Auditor** ([1995]), with competence certified by passing the formal ASQ written examination for Certified Quality Auditor.
- B. The numerous formal Technical Courses that Dr. King has successfully completed include:
 - 1. **ASQ Certified Quality Manager Course** (2001)
 - 2. **13th Annual ASQ Quality Management Conference** (2001) including:
 - a. Quality in a Lean Organization,
 - b. Tools of Six Sigma,
 - c. Navigating Your Organization Through the ISO 9000:2000 Transition,
 - d. Using the Theory of Constraints to Resolve the Quality Dilemma,
 - e. Using Quality Tools to Improve Performance Excellence in the Day-to-Day Operations, and
 - f. Certification: The Next Step for Quality Managers
 - 3. **25th International GMP Conference and Aseptic Processing Tutorial** (2001)
 - 4. **23rd International GMP Conference and How To Prepare For Your FDA Inspection: A Practical Approach** (1999);
 - 5. **FDA-sponsored training on 21 CFR 11** (1999);
 - 6. **FDA Global Inspections** (1998);
 - 7. **Current FDA Views on Pharmaceutical Laboratory Operations and CGMPs** (1998);
 - 8. **Computer Validation & Aspects of Process and Equipment Validation** (1997);
 - 9. **Interfacing with the FDA** (1997);
 - 10. **Pre-Approval Inspection** (1996);
 - 11. **Quality Auditing** (1995);
 - 12. **Pharmaceutical Validation** (1995);
 - 13. **Software Audits** (1993), "TESTING COMPUTER SYSTEMS IN PHARMACEUTICAL APPLICATIONS," given by **Confidence in Software**. The 3-day course covered:
 - a. **FDA** Requirements,
 - b. Planning Validation,
 - c. Validation Preparation,
 - d. Testing Modules,
 - e. Testing Interfaces,
 - f. Challenging Functions,
 - g. Challenging the System,
 - h. Conducting the Challenge, and
 - i. Acceptance Testing.
 - 14. **Various Aspects of the Pharmaceutical Industry** (1991);

- 15 Quality Assurance for Laboratories (1989);
16. *Perkin-Elmer LIMS/CLAS System Management and Operation* (1984) (Laboratory Information management System ["LIMS"] and Computerized Laboratory Acquisition System ["CLAS"]);
17. Laboratory Automation and Quality Control (1984);
18. Personnel Supervision (1981); and
19. General Management (1978).

C. From September 1970 through March 1971, he studied:

1. The formalized process by which software is defined, stated, written, debugged, tested and verified in a controlled documented manner,
2. Programming in several IBM System 360 languages (including Basis Assembly Language [BAL], FORTRAN 66, COBOL, and PL/1), and
3. The Fundamentals of Systems Analysis (including project planning, PERT charting, project auditing and review, and systems' standards).

In 1971, **COMPUTER LEARNING CENTERS, INC.** of Rockville, Maryland awarded him an honors diploma in "**Computer Programming and Systems Analysis.**" Dr. King went on to apply when he completed his active duty military service 1971 and returned to Emory University to successfully pursue his Ph.D.

PUBLICATIONS BY PAUL G. KING

1969

1. **The Coordination Chemistry of Tantalum (V)**, 48+ pages (master's thesis) Ann Arbor Press 1969
2. Coordination Compounds of Niobium (V) and Tantalum (V) Chloroalkoxides with Ligands Related to beta-Diketones, *Journal of Less-Common Metals* (1969); **19**: 141-149, with R. C. Johnson *et al.*

1974

1. Computers and Experimental Optimization. *Research/Development*, 1974; **25**(5): cover and pages 22-24 & 26, with Stanley N. Deming.
2. **Automated Development of Analytical Methods**, 443+ pages (Ph.D. Dissertation that won a Sigma XI Award for Excellence) Ann Arbor Press 1974.
3. UNIPLEX: Single-Factor Optimization of Response in the Presence of Error. *Analytical Chemistry* 1974; **46** (11): 1476-1481, with Stanley N. Deming.

1975

1. DIFFICULTIES IN THE APPLICATION OF SIMPLEX OPTIMIZATION TO ANALYTICAL CHEMISTRY. *Analytical Letters* 1975; **8** (5): 369-376, with Stanley N. Deming and Stephen L. Morgan.

1984

1. Laboratory Automation and Information Management. *Analytical Instruments and Computers* 1984; **1**: 45-47.
2. Laboratory Computerization and Good Laboratory Practice Standards (GLPS). *Anal Instruments and Computers* 1984; **2**: 14-15.
3. Quality Assurance and Computerization in the Regulated Laboratory. *Computerized Applications in the Laboratory* 1984; **2**: 298-304.

1985

1. Intelligence in Instruments. *Instruments & Computers* 1985; **3**: 4-5.

1996

1. Articles in **The AOAC International's** periodical, *The Referee*, in 1996 on:
 - a. Business and the Laboratory;
 - b. Twentieth International Good manufacturing Practices Conference (in two parts);
 - c. ISO/IEC Guide 25 and Laboratory Competence;
 - d. Safe Handling of Hazardous Materials, Carcinogens and Biohazards.
2. Altered Dynamics for USP Apparatus 2. *Dissolution Technologies* 1996; **3**(3): 8-12.

1997

1. Bringing a Chinese Bulk Pharmaceutical Chemical Manufacturer Up to FDA Expectations. *J. cGMP Compliance* 1997 April; **1**(3): 38-43.
2. The Future of Validation A Validation "Life Cycle" Journey. *J. Validation Technology* 1997 May; **3**(3): 296-297.

3. ISO/IEC Guide 25, An International Quality System Standard, and the FDA-Regulated Laboratory. *J. cGMP Compliance* 1997 July; **1**(4): 25-35.
4. Equipment Validation A Logical Approach to the Pharmaceutical “Life Cycle” Journey - Part I of a Series -. *J. Validation Technology* 1997 August; **3**(4): 345-354.
5. Process Validation for Existing Processes A Logical Approach to the Pharmaceutical “Life Cycle” Journey - Part II of a Series -. *J. Validation Technology* 1997 November; **4**(1): 53-64.

1998

1. Process Validation for New Processes A Logical Approach to the Pharmaceutical “Life Cycle” Journey - Part III of a Series -. *J. Validation Technology* 1998 May; **4**(3): 234-242.
2. A Direct Approach to Determining The Valid Linear Range for A Comparative Method that Uses a Single Standard, *Scientific Computing & Automation* 1998 June: 63-64.
3. Improving cGMP Training Programs – Part One of a Two-part Series -. *J. cGMP Compliance* 1998 June; **2**(4): 56-63.
4. Improving cGMP Training Programs – Part Two of a Two-part Series -. *J. cGMP Compliance* 1998 October; **3**(1): 78-85.
5. Recommended Revisions to Several USP Standards. *Pharmaceutical Forum* 1998 November: **24**(6): 7343-7348.

1999

1. HPLC METHOD DEVELOPMENT AND VALIDATION: A Direct Procedure For Determining An HPLC Method's “Linear Through Zero” Range. *LC•GC* 1999 January; **17**(1): 46, 48, 50.
2. An Empirical Algorithm For Dissolution Profile Calculations. *Scientific Computing & Instrumentation*, March 1999: 76-77.
3. Process Validation – Establishing the Minimum Process Capability for a Drug-Product Manufacturing Process (Part 1 of 2: The Basics). *Pharmaceutical Engineering* 1999 November/December: **19**(6): 8-16, 74-86.

2000

1. Process Validation – Establishing the Minimum Process Capability for a Drug-Product Manufacturing Process (Part 2 of 2: Content Uniformity Examples and Extension to Other USP Tests). *Pharmaceutical Engineering* 2000 March/April; **20**(2): 72-88.

2004

1. An “American Mystery Disease”? *Medical Veritas*, 2004 November; **1**(2): 304.
2. The best medicine that money can buy? *Medical Veritas*, 2004 November; **1**(2): 305-312.

2005

1. Mercury Emissions, August 2005; 4 pages. <http://www.mercury-freedrugs.org>
2. Thimerosal Causes Mercury Poisoning I– A Rebuttal to Dr. Novella's Views, September 2005; 99 pages. <http://www.mercury-freedrugs.org>
3. Thimerosal Causes Mercury Poisoning III – Rebuttal To Dr. Orenstein's Views, 21 October 2005; 38 pages. <http://www.mercury-freedrugs.org>
4. Dr. King's Rebuttal to WSJ 051022 Pro Pharma Editorial for S_1873, “Bioshield II”, 30 October 2005; 6 pages. <http://www.mercury-freedrugs.org>

5. Thimerosal Causes Mercury Poisoning II – Rebuttal To Dr. Offit's Views, November 2005; 30 pages. <http://www.mercury-freedrugs.org>
6. Thimerosal & Mercury Poisoning – Draft Review of CDC's 050922 Q&A on the Flu Vaccines, November 2005; 30 pages. <http://www.mercury-freedrugs.org>
7. Fearmongering – Flu Vaccines & Pandemic Scares – Marketing Mercury Poisoning?, November 2005; 3 pages. <http://www.mercury-freedrugs.org>
8. Critical assessment of CDC's “Questions and answers: Thimerosal-containing influenza vaccine.” *Medical Veritas*, 2005; **2**(2): 703-720.
9. Dr. King's Response To Dr Mike Fitzgerald's 051109 “When Quackery Kills,” 9 November 2005; 16 pages. <http://www.mercury-freedrugs.org>
10. Thimerosal Causes Mercury Poisoning IV – Review Of Dr Darshak Sanghavi's 051204 “The Secret Truth” Article, 6 December 2005; 34 pages. <http://www.mercury-freedrugs.org>
11. Dr. King's Review 051221 of Vaccine Liability- Congress Should Give Vaccines Shot in the Arm, 21 December 2005; 15 pages. <http://www.mercury-freedrugs.org>
12. Autism Speaks' Policy Statement On Mercury and Vaccines 051222 Draft Review, 22 December 2005; 7 pages. <http://www.mercury-freedrugs.org>

2006

1. Review of HR2863's Pandemic Flu Provisions & PREP_Act, 3 January 2006; 33 pages. <http://www.mercury-freedrugs.org>
2. Thimerosal Causes Mercury Poisoning V – Review Chambers & McIntyre's “When Science Is Not Enough” Article, 15 February 2006; 82 pages. <http://www.mercury-freedrugs.org>
3. Thimerosal Causes Mercury Poisoning VI – Review Of Pro-Thimerosal Groups' Letter To Congress, 9 April 2006; 15 pages. <http://www.mercury-freedrugs.org>
4. Thimerosal Causes Mercury Poisoning VII – Rebuttal to “Beyond the Headlines: Link still claimed between thimerosal and autism” *Rev.* 3, 3 July 2006; 28 pages. <http://www.mercury-freedrugs.org>
5. Thimerosal Causes Mercury Poisoning VIII – Mercury-poisoning the Public: The case against the Thimerosal-preserved vaccines [a rebuttal to “Don't ban thimerosal ...”], 30 June 2006; 8 pages. <http://www.mercury-freedrugs.org>
6. Commentary: Thimerosal—what the Lister Hill transcript did not clearly state! *Medical Veritas*, 2006; **3**(1): 821-826.
7. Editorial – Thimerosal: Proven systemic human poison, immunogen and autoimmunogen, and suspect human, proven animal teratogen. *Medical Veritas*, 2006; **3**(1): 914-915.
8. Thimerosal Causes Mercury Poisoning IX – Immunization Issues [a rebuttal to “Arsenal of immunizations ...”] *Rev.*, 30 July 2006; 22 pages. <http://www.mercury-freedrugs.org>
9. Thimerosal Causes Mercury Poisoning X – Link Between Thimerosal and Pervasive Developmental Disorders [Draft Rebuttal to Fombonne et al.'s “Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations”], 27 August 2006; 102 pages. <http://www.mercury-freedrugs.org>
10. Thimerosal Causes Mercury Poisoning XI – Draft Rebuttal to the Opinions of Peter Hotez and Rosalynn Carter in their article, “Act could turn the tide on common birth defect,” 27 August 2006; 73 pages. <http://www.mercury-freedrugs.org>
11. Geier DA, King PG, Geier MR. Influenza vaccine: Review of effectiveness of U.S. vaccination program, and policy considerations. *J Am Phys & Surg.* 2006 Fall; **11**(3): 69-74.

12. Thimerosal Causes Mercury Poisoning XII – Draft Response to the DHHS Letter Date-stamped “AUG 25 2006” – The DHHS's Response to “An Open Letter to the American Public” posted on the Internet on 9 April 2006, 9 September 2006; 60 pages. <http://www.mercury-freedrugs.org>
13. CoMeD's Petition to FDA for a STAY under 21 CFR Sec 10.35, 21 October 2006; 130 pages. FDA Docket 2004P-0349/PSA1 filed 24 October 2006 by FDA Division of Dockets Management.
14. CoMeD Response to FDA Letter Date-Stamped “DEC 21 2006,” December 24, 2006, 5 pages. <http://www.mercury-freedrugs.org>
15. CoMeD Review of NJ Dept Health & Senior Services Letter About Influenza Vaccines: Ineffective & A Mercury-poisoning Vector, 27 December 2006; 11 pages. <http://www.mercury-freedrugs.org>

2007

1. CoMeD's Recommendations for Changes to Revisions Proposed by the NJ Dept Health and Senior Services to N.J.A.C. 8:57-4, Immunization of Pupils in School, 24 January 2007; 14 pages. <http://www.mercury-freedrugs.org>
2. CoMeD Rebuttal to “For the Good of the Herd,” an op-ed piece by Arthur Allen published online on January 25, 2007 by the New York Times, 25 January 2007; 12 pages. <http://www.mercury-freedrugs.org>
3. Review of Kevin Leitch's Critique of “Autistic Children Clinically Proven Mercury Poisoned,” April 2007, 12 pages. <http://www.mercury-freedrugs.org>
4. Thimerosal Causes Mercury Poisoning XIII – Rebuttal to an editorial in Nature Neuroscience 2007; 10: 531, “Silencing debate over autism,” 6 May 2007; 18 pages. <http://www.mercury-freedrugs.org>
5. Thimerosal Causes Mercury Poisoning XIV – Updated Review of “Another Salvo in the Mercury/Autism Controversy” By Stephan Novella, 18 May 2007; 16 pages. <http://www.mercury-freedrugs.org>
6. The Deadly Panacea: Vaccines, Immunity & Corporate Science. *ACRES USA* May 2007; **37**(5): 56-60.
7. Critical assessment of an FDA letter concerning a Citizen Petition specifying actions against Thimerosal-containing drugs. *Medical Veritas*, 2007; **4**(1): 1282-1370.
8. Note regarding filing of 2007P-0331 – submitted for publication, 24 August 2007; 1 page. <http://www.mercury-freedrugs.org>
9. 2007P-0331 Ban Use of Mercury In Medicine, UNLESS Proven Toxicologically Safe to the CGMP Standard Sufficiently Nontoxic, 24 August 2007; “447” pages. <http://www.mercury-freedrugs.org>
 - 9.1 2007P-0331 Ban Use of Mercury In Medicine, UNLESS Proven Toxicologically Safe to the CGMP Standard Sufficiently Nontoxic: Initial remarks, signature pages, supporting organizations, outline, and references listing, 10 August 2007; 25 pages. <http://www.mercury-freedrugs.org>
 - 9.2 2007P-0331 Ban Use of Mercury In Medicine, UNLESS Proven Toxicologically Safe to the CGMP Standard Sufficiently Nontoxic: Formal Citizen Petition text, “10 August 2007”; 422 pages <http://www.mercury-freedrugs.org>
10. Instructions for Submitting Comments to FDA Docket # 2007P-0331, 30 August 2007; 2 pages. <http://www.mercury-freedrugs.org>
11. Thimerosal Causes Mercury Poisoning XV – Mercury Poisoning by Thimerosal in Vaccines – A Rebuttal to the Doublespeak in: “On Vaccines, Immune to Reason” By Paul Howard, 18 October 2007; 19 pages. <http://www.mercury-freedrugs.org>

12. Thimerosal Causes Mercury Poisoning XVI – No Proof Of Safety for Thimerosal in Vaccines – A Rebuttal to the Doublespeak in: “Suffer the Little Children” No More By Michael Fumento, 29 October 2007; 20 pages. <http://www.mercury-freedrugs.org>
13. A Rebuttal to the Doublespeak in: “Parents, officials struggle over right to refuse vaccines” By Logan Molyneux, 25 November 2007; 39 pages. <http://www.mercury-freedrugs.org>
14. A Review of Parental Dilemma: “To Get Kids Immunized or Not” By Allen Mask, M.D., 28 November 2007; 15 pages. <http://www.mercury-freedrugs.org>
15. A Review of the Doublespeak in: “Vaccines and Autism: Myths and Misconceptions” By Steven Novella (18 December 2007; 63 pages. <http://www.mercury-freedrugs.org>

2008

1. A Review of: "Vaccinations are still needed for kids" By Meg Fisher, MD, 27 January 2008; 27 pages. <http://www.mercury-freedrugs.org>
2. RotaTeq vaccine adverse events and policy considerations. *Medical Science Monitor*, 2008 March; **14**(3): PH9-PH16, with David A. Geier, Lisa K. Sykes and Mark R. Geier.
3. An UPDATED Review of the Doublespeak in: “Vaccines and Autism: Myths and Misconceptions” By Steven Novella, 31 March 2008; 75 pages. <http://www.mercury-freedrugs.org>
4. Key realities about autism, vaccines, vaccine-injury compensation, Thimerosal, and autism-related research. *Medical Veritas* 2008 April; **5**(1): 1610-1644 with Gary S. Goldman.
5. A rebuttal to the doublespeak in “Parents, officials struggle over right to refuse vaccines”. *Medical Veritas* 2008 April; **5**(1): 1645-1666.
6. A Review of: “Vaccines and Autism Revisited - The Hannah Poling Case” [An article by Paul A. Offit, M.D. *NEJM* 2008 May 15; **358**: 20], 30 May 2008; 13 pages. <http://www.mercury-freedrugs.org>
7. A Review of: “VACCINATIONS Faith Lets Some Kids Skip Shots” [An article by Sandra G. Boodman, Staff Writer, *Washington Post*, June 10, 2008], 27 June 2008; 15 pages. <http://www.mercury-freedrugs.org>
8. A Review of: “Autism Myth Lives On” [An article by Assoc. Prof. Sam Wang, USA Today on-line April 16, 2008], 30 June 2008; 15 pages. <http://www.mercury-freedrugs.org>
9. A Review of: “Experts to Discuss One Puzzling Case, as a Second Case Has Arisen” [An article by Gardiner Harris, Reporter, NY Times on-line June 27, 2008], 11 July 2008; 27 pages. <http://www.mercury-freedrugs.org>
10. A Review of: “Vaccine safety: genuine concern or a legacy of unfounded skepticism.” *Expert Reviews of Vaccines* 2008; **7**(3): 275-277. Chatterjee A., 27 July 2008; 40 pages. <http://www.mercury-freedrugs.org>
11. A Review of: “As Diseases Make Comeback, Why Aren't All Kids Vaccinated?” Popular Mechanics Magazine on-line. Reynolds GH, 30 July 2008; 30 pages. <http://www.mercury-freedrugs.org>
12. Thimerosal in Vaccines: Inconvenient Reality, 29 August 2008; 6 pages. <http://www.mercury-freedrugs.org>
13. A Draft Review of: “Florida Governor's Task Force on Autism Spectrum Disorders- Task Force Requests to the Florida DoH”, Part 1, 17 October 2008; 68 pages. <http://www.mercury-freedrugs.org>
14. A Draft Review of: “Florida Governor's Task Force on Autism Spectrum Disorders- Task Force Requests to the Florida DoH”, Part 2, 17 October 2008; 77 pages. <http://www.mercury-freedrugs.org>
15. A Draft Response To: “The Position of the New Jersey Department of Health and Senior Services (NJ DHHS) on: The Pending New Jersey Conscientious Exemption Legislation”, 5 November 2008; 18 pages. <http://www.mercury-freedrugs.org>

16. "A Draft Response To: 'Vaccines: Separating fact from fiction, 28 Nov. 2008; 37 pages. <http://www.mercury-freedrugs.org>

2009

1. A Draft Response To: "Some parents oppose New Jersey's new flu vaccination law", 28 Jan. 2009; 12 pages. <http://www.mercury-freedrugs.org>
2. Draft: Proposed Safety Limits For Organic Mercury Exposure And Thoughts On The Mercury Poisoning Of Developing Children, 15 March 2009; 5 pages. <http://www.mercury-freedrugs.org>
3. Mitochondrial Dysfunction, Impaired Oxidative-Reduction Activity, Degeneration, and Death in Human Neuronal and Fetal Cells Induced by Low-Level Exposure to Thimerosal and Other Metal Compounds. *Toxicological & Environmental Chemistry* 2009; **91**: 735-749. with David A. Geier and Mark R. Geier, MD,PhD. <http://www.mercury-freedrugs.org>
4. Draft: Review of the FDA's "Thimerosal in Vaccines Questions and Answers", 9 July 2009; 75 pages. <http://www.mercury-freedrugs.org>
5. Formal Review of the FDA's: "Thimerosal in Vaccines Questions and Answers", 18 July 2009; 76 pages. <http://www.mercury-freedrugs.org>
6. E-mail: Information quality request seeking corrections, 24 July 2009; 3 pages. <http://www.mercury-freedrugs.org>
7. The "No Thimerosal-Preserved Vaccines" Lie, 12 August 2009; 9 pages. <http://www.mercury-freedrugs.org>
8. The "Truth" About The Toxicity Of Thimerosal, 12 August 2009; 6 pages. <http://www.mercury-freedrugs.org>
9. The Rise of Diseases "Caused" by Sub-acute Hg Poisoning, 12 August 2009; 9 pages. <http://www.mercury-freedrugs.org>
10. Draft Review of the CDC's 'General Questions and Answers on Thimerosal' (25 October 2009, 22 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
11. Updated Editorial on Sub-Acute Mercury (Hg) Poisoning By Medicine: The Rise of Diseases 'Caused' by Sub-acute Hg Poisoning via Medicine (29 November 2009, 12 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
12. Misleading Mercury-exposure Comparisons: Thimerosal-preserved Flu Shot Versus the Eating of Tuna Fish (29 November 2009, 5 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
13. Draft: Why do media report 'the other side' of scientific facts -- One Scientist's Response! (25 December 2009; 21 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
14. NOTE: CDC's reporting of historical 'autism' incidence and maximum mercury exposure from CDC-recommended vaccination programs" (30 December 2009; 6 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>

2010 [excluding articles published in peer-reviewed journals in which Dr. King is a named author]

1. One Scientist's Response to: 'Vaccine Scares, The Worst Ideas of the Decade' (1 January 2010; 15 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
2. Draft Review of Michael Fumento's "The damage done" (28 February 2010; 32 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
3. Bruesewitz v. Wyeth: A layperson's abbreviated views: The 7th Amendment to the Constitution of the USA, the National Vaccine Injury Compensation Program (NVICP) [42 U.S.C. § 300aa-10 et seq.], and Wyeth's absolute, nondischargeable duty to prove that its DTP vaccine was safe (2 April 2010; 10 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
4. Thimerosal in Vaccines: A 'Profitable' Medical Population-Maiming Agent? (23 June 2010; 9 pages) <http://www.dr-king.com>
5. Parallels in New Delhi, India: An Epidemic Induced By Added Doses Of Thimerosal-Preserved Vaccines (11 July 2010, 5 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>

6. Draft Review of recent publications that show Thimerosal-preserved vaccines are major cause of current chronic-condition 'autism' epidemic (25 July 2010; 27 pages)" <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
7. Revised Review of recent publications that show Thimerosal-preserved vaccines are major cause of current chronic-condition 'autism' epidemic (28 July 2010; 27 pages)" <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
8. Draft: FORMAL REVIEW OF: The FDA's "2010-2011 Influenza Season Vaccine Questions and Answers" (25 August 2010; 32 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
9. Draft: REVIEW: Another False 'Whooping Cough Epidemic' Warning: 'California declares whooping cough epidemic - Santa Clara County fears worst year in 50 years' (27 August 2010; 12 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
10. Vaccines, Vaccination Programs, and Knowing Misrepresentations (1 October 2010; 18 pages) <http://www.mercury-freedrugs.org> and <http://www.dr-king.com>
11. Thimerosal: Mercury metabolism and distribution in laboratory rats? (in review for publication in December 2010; 10 pages)

OTHER DOCUMENTS & COMMENTS DIRECTLY (OR INDIRECTLY, THROUGH THE FEDERAL COURTS) SUBMITTED TO THE FDA

By Paul G. King

1. Formal comments on the FDA's "Current Good Manufacturing Practice; Proposed Amendment of Certain Requirements for Finished Pharmaceuticals," IN SEPTEMBER 1997.
2. "In-Process 'Powder' Blend Sampling And Evaluation (And Appropriate In-Process and Final Release Specifications)," A WHITE PAPER, JANUARY 1998. [This condensed white paper was submitted to certain key industry and FDA administrators at the 23rd International GMP Conference held in March 1999 at the University of Georgia in Athens, GA. The Agency has reviewed, commented on, and provided a formal response (late in 1999) on one of the key issues discussed (in-process mix uniformity testing).]
3. Formal comment on FDA's proposed 21 CFR 26, "Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, And Certain Medical Device Premarket Evaluation Reports Provide By European Community Member State Regulatory Authorities And European Community Conformity Assessment Bodies" in May 1998. [Agency ignored or misrepresented comments when they responded to them.]
4. Formal comment on FDA's proposed "Draft Guidance for Industry on ANDA's Impurities in Drug Substances (.../guidance/2452dft.pdf)," Docket: 98D-0777, reopened in *Federal Register*, **63**, of October 19, 1998.
5. Formal comment on FDA's proposed "Draft Guidance for Industry on Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production (.../guidance/1212dft.pdf)," Docket: 98D-0777, *Federal Register*, **63**(189), 52276-52277, Wednesday, September 30, 1998.
6. Remarks presented to FDA at "FDAMA Stakeholder Meeting," Wednesday, 28 April 1999 In Philadelphia, PA.
7. "QUALITY CONTROL AND STATISTICS?" A GUIDANCE WHITE PAPER, JULY 2001, pp. 87. [For one-day training seminar at FDA's CDER Division of Manufacturing and Product Quality in Rockville, MD.]
8. "QUALITY CONTROL AND STATISTICS" A GUIDANCE WHITE PAPER, DECEMBER 2002, pp. 194. [With copying privileges to FDA, CDER, Division of Manufacturing and Product Quality]
9. Initial Remarks To Docket: 03N-0059, "Pharmaceutical Current Good Manufacturing Practices for the 21st Century: A Risk-Based Approach," Comment Number: EC -1 and -2, Accepted, Volume 1, 01 March 2003.
10. "A Scientific Review of PQRI December 2002 Report, 'THE USE OF STRATIFIED SAMPLING OF BLEND AND DOSAGGE UNITS TO DEMONSTRATE ADEQUACY OF MIX FOR POWDER BLENDS,'" A TECHNICAL REVIEW FOR THE FDA, MARCH 2003, pp. 87 (pp. 42 w/o APPENDICES).
11. E-mail Comments to FDA (pat@cder.fda.gov) on Agency's Risk -Based Approach to CGMP, submitted 1 March 2003
12. E-mail Comments to Docket: 03D-0060: "Draft Guidance: Part 11, Electronic Records, Electronic Signatures Scope and Application," 22 March 2003
13. E-mail Comments to Docket 03D-0059 - "A Risk-Based Approach to CGMP," 24 March 2003.
14. Initial Formal Comment To Docket 02D-0526 - "Draft Guidance for Industry on Drug Product: Chemistry, Manufacturing, and Controls Information; Availability," pp. 22; posted 8 April 2003
15. Initial Formal Comments To Docket 03D-0061 - "Draft Guidance, Comparability Protocols - Chemistry, Manufacturing, and Controls Information," pp. 14; posted 15 May 2003"
16. Updated Formal Comment To Docket 02D-0526 - "Draft Guidance for Industry on Drug Product: Chemistry, Manufacturing, and Controls Information; Availability," pp. 22; submitted 9 May 2003.

17. Updated Formal Comments To Docket 03D-0061 – “Draft Guidance, Comparability Protocols — Chemistry, Manufacturing, and Controls Information,” pp. 14, submitted 9 May 2003.
18. Review of Formal Comments To Docket 02D-0526 – “Draft Guidance for Industry on Drug Product: Chemistry, Manufacturing, and Controls Information; Availability,” pp. 279+; submitted 30 September 2003.
19. “Scientific Review of PQRI Dec 2002 'Recommendation' report-a.pdf,” pp. 90, submitted 30 September 2003 [to Dr. Ajaz E. Hussain, Deputy Director of Office of Pharmaceutical Science (OPS) in FDA CDER – on or about 17 October 2003 assigned Jon E. Clark, Associate Director for Policy Development, OPS, CDER, FDA].
20. Review of CDER’s Office of Pharmaceutical Science’s “Draft Guidance for Industry on PAT—A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance,” pp. 42+, submitted 12 October 2003.
21. Review of Comments to Docket 03D-0061 – “Draft Guidance, Comparability Protocols — Chemistry, Manufacturing, and Controls Information,” pp. 171+; submitted 21 October 2003.
22. Formal Comments to Docket 03D-0380 – “Draft Guidance for Industry on PAT—A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance,” pp. 45+; submitted 30 October 2003.
23. Formal Comments to Docket 03D-0493 – “Draft Guidance for Industry on Powder Blends and Finished Dosage Units - Stratified In-Process Dosage Unit Sampling and Assessment,” pp. 69+, submitted 15 November 2003.
24. Formal Comments to Docket 03D-0380 – “REVISED Draft Guidance for Industry on PAT – A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance,” pp. 36+, submitted 6 January 2004.
25. Formal Comments to Docket 03D-0493 – “REVISED Draft Guidance for Industry on Powder Blends and Finished Dosage Units – Powder Blends And Dosage Units – In-Process Blend And Dosage Unit Inspection (Sampling And Evaluation) For Content Uniformity,” pp. 48+, submitted 21 January 2004.
26. Initial Formal Comments to Docket 03D-0571 – “Draft Guidance for Industry on Drug Substance; Chemistry, Manufacturing, and Controls Information; Availability,” pp. 42+, submitted 6 February 2004.
27. Review of Comments Submitted to Docket 03D-0493 – “Draft Guidance for Industry on Powder Blends and Finished Dosage Units – Stratified In-Process Dosage Unit Sampling and Assessment,” pp. 244+, Submitted 30 April 2004.
28. Addendum to Review of Comments Submitted to Docket 03D-0493 – “Draft Guidance for industry on Powder Blends and Finished Dosage Units – Stratified In-Process Dosage Unit Sampling and Assessment,” pp. 42+, Submitted 6 May 2004.
29. Formal Comments to Docket 03D-0493 – “Second Revision to Draft Guidance for Industry on Powder Blends and Finished Dosage Units – Powder Blends And Dosage Units – In-Process Blend And Dosage Unit Inspection (Sampling And Evaluation) For Active Uniformity,” pp. 64+, Submitted 15 May 2004.
30. Submission to Docket 03D-0493 – “Guidance for Industry on Powder Blends And Dosage Units – Blend And Dosage Unit Inspection (Sampling And Evaluation) For Active Uniformity,” A second proposed revision of the Agency’s draft Guidance, pp. 66, Submitted 15 May 2004 (Posted 7 June 2004).
31. Formal Comments to Docket 04N-0181 – “Critical Path Initiative; Establishment of Docket,” An in-depth review of Agency’s “Critical Path” white paper and formal comments on the true “critical” impediments to safer and truly better medical products, pp. 96+, Submitted 18 June 2004.

32. **CoMeD** Citizen Petition, Docket 2004P-0349 – “CITIZEN PETITION REQUESTING CERTAIN ACTIONS WITH RESPECT TO VACCINES AND OTHER DRUG PRODUCTS, CONTAINING ADDED MERCURY, IN ORDER TO REDUCE THE HEALTH RISK TO SUSCEPTIBLE FETUSES, NEWBORNS, CHILDREN, ADOLESCENTS AND ADULTS,” pp. 61+, Filed 4 August 2004 (FDA Docket # 2004P-0349/CP1).
33. Formal 'SIGNIFICANT ADVERSE COMMENTS' to Docket 2004N-0214 – “Public Information Regulations, Direct Final Rule”, pp. 9, Submitted 28 September 2004.
34. Formal Comments to a 'Citizen Petition' submitted by the National Vaccine Information Center (NVIC) in December of 2001 and Posted To The FDA's Public Docket 02P-0025 - “Immediate suspension all vaccines containing Thimerosal*,” pp. 19+, Submitted 30 September 2004.
35. Formal Comments to Docket 2004D-0443 - “Draft Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,” pp. 30+, Submitted 24 November 2004.
36. Formal Docket Comments' Review Comment To: Docket 2004D-0443 - “Draft Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,” pp 192+, Submitted 18 January 2005.
37. Formal “*Revised Draft Guidance*” Comment To: Docket 2004D-0443 - “Draft Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations.” pp. 39+, Submitted 18 January 2005.
38. Revision Rationale Comments For: “*The Revised Draft Guidance*” Comment To: Docket 2004 D-0443 - “Draft Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations.” pp. 18+, Submitted 18 January 2005.
39. Formal **CoMeD** Response Letter to FDA's 180-day-response letter to **CoMeD**'s Citizen Petition, Submitted To: Docket 2004P-0349, titled, "Action on Products containing added Mercury" by the FDA, pp 19, Submitted 23 February 2005; Posted to Docket on 02 March 2006.
 ... [Numerous additional comments to the FDA concerning the original **CoMeD** Citizen Petition and the illegal actions taken by FDA appertaining thereto; another **CoMeD** Citizen Petition and the correspondence arising there from; and numerous legal filings in 2 federal lawsuits seeking to have the U.S. Federal Courts compel the Commissioner of the FDA and the Secretary of HHS to comply with the laws governing the conduct of their reports in a manner that complies with federal statutes (42 U.S.C. § 300aa-27 and 21 U.S.C. § 351(a)(2)(B)) and the operational regulations (e.g., 21 CFR § 601.4) governing the conduct of federal administrative personnel (one of which is still being litigated) as well as contributions to other filed and/or pending federal litigation on vaccine issues.]
- ~60. Formal **CoMeD** Docket Comments' Review Comment To: FDA Docket: FDA-2010-N-0099 - [RIN 0910-AG15] "Revision of the Requirements for Constituent Materials" [FDA-2010-N-0099-0007.1.pdf] pp 10, Submitted 25 June 2010.